{"id":"NCT02867813","sponsor":"Amgen","briefTitle":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension","officialTitle":"A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-02","primaryCompletion":"2022-03-21","completion":"2022-03-21","firstPosted":"2016-08-16","resultsPosted":"2023-02-28","lastUpdate":"2023-04-07"},"enrollment":5035,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Dyslipidemia"],"interventions":[{"type":"BIOLOGICAL","name":"Evolocumab","otherNames":[]}],"arms":[{"label":"evolocumab (AMG 145)","type":"EXPERIMENTAL"}],"summary":"The primary clinical hypothesis is that long-term exposure of evolocumab will be safe and well tolerated in subjects with clinically evident atherosclerotic cardiovascular disease (CVD).","primaryOutcome":{"measure":"Number of Participants Who Experienced an Adverse Event","timeFrame":"Up to 5 years","effectByArm":[{"arm":"Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study","deltaMin":2144,"sd":null},{"arm":"Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study","deltaMin":2084,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":198,"countries":["United States","Czechia","Hungary","Poland","Russia","Slovakia","Ukraine"]},"refs":{"pmids":["36031810","36779348"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":1077,"n":2532},"commonTop":["Hypertension","Upper respiratory tract infection","Bronchitis","Nasopharyngitis","Arthralgia"]}}